Identification of potential novel drivers and biomarkers of CDK4/6 inhibitor resistance in metastatic breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Hamburg, Universität Hamburg, Dissertation, 2022
- Keyword
-
Brustkrebs
Krebs
Therapie
- Event
-
Veröffentlichung
- (where)
-
Hamburg
- (who)
-
Staats- und Universitätsbibliothek Hamburg Carl von Ossietzky
- (when)
-
2022
- Creator
-
Ott, Leonie Florence
- Contributor
-
Pantel, Klaus
Kehr, Julia
- URN
-
urn:nbn:de:gbv:18-ediss-103209
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ott, Leonie Florence
- Pantel, Klaus
- Kehr, Julia
- Staats- und Universitätsbibliothek Hamburg Carl von Ossietzky
Time of origin
- 2022
Other Objects (12)
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors
Hämatologische Toxizitäten von CDK4/6 Inhibitoren
Monitoring CDK4/6 inhibitor resistance in metastatic breast cancer patients using liquid biopsy markers
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays
Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede
Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast
CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors
Hämatologische Toxizitäten von CDK4/6 Inhibitoren
Monitoring CDK4/6 inhibitor resistance in metastatic breast cancer patients using liquid biopsy markers
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays
Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede
Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast
CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors
Hämatologische Toxizitäten von CDK4/6 Inhibitoren
Monitoring CDK4/6 inhibitor resistance in metastatic breast cancer patients using liquid biopsy markers
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays
Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede
Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast
CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer